His specific research interests are in the identification, interception and precision prevention of gastrointestinal cancers and other diseases. He has a specialized expertise in clinical trial design and implementation, especially with respect to studies of the gut microbiome and precision risk biomarkers. His research is highly collaborative and achievements have been nationally and internationally recognized by professional organizations, including the American Association for Cancer Research, the American Gastroenterological Association, and Aspirin for Cancer Prevention/European Hereditary Tumor Group. He is funded by the NIH/NIDDK (K01DK120742), the American Gastroenterological Association, and is an NIH Loan Repayment Ambassador through the NCI (L30CA209764). He is an early career investigator on the Stand Up To Cancer Gastric Cancer Early Detection and Interception Team, the Stand Up to Cancer Colorectal Cancer Health Equity Dream Team, and within the Clinical Center for NIH's Nutrition for Precision Health.